Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 163

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

Open access
Segeren, Christine M., Sonneveld, Pieter, van der Holt, Bronno, Vellenga, Edo, Croockewit, Alexandra J., Verhoef, Gregor E. G., Cornelissen, Jan J., Schaafsma, Martijn R., van Oers, Marinus H. J., Wijermans, Pierre W., Fibbe, Wim E., Wittebol, Shulamit, Schouten, Harry C., Kooy, Marinus van Marwijk, Biesma, Douwe H., Baars, Joke W., Slater, Rosalyn, Steijaert, Monique M. C., Buijt, Ivon, Lokhorst, Henk M. · 2003 · Blood

Abstract

We compared the efficacy of intensified chemotherapy followed by myeloablative therapy and autologous stem cell rescue with intensified chemotherapy alone in patients newly diagnosed with multiple myeloma. There were 261 eligible patients younger than 66 years with stage II/III multiple myeloma who were randomized after remission induction therapy with vincristine, adriamycin, dexamethasone (VAD) to receive intensified chemotherapy, that is, melphalan 140 mg/m2 administered intravenously in 2 doses of 70 mg/m2 (intermediate-dose melphalan [IDM]) without stem cell rescue (n = 129) or the same regimen followed by myeloablative therapy consisting of cyclophosphamide, total body irradiation, and autologous stem cell reinfusion (n = 132). Interferon-α–2a was given as maintenance. Of the eligible patients, 79% received both cycles of IDM and 79% of allocated patients actually received myeloablative treatment. The response rate (complete remission [CR] plus partial remission [PR]) was 88% in the intensified chemotherapy group versus 95% in the myeloablative treatment group. CR was significantly higher after myeloablative therapy (13% versus 29%; P = .002). With a median follow-up of 33 months (range, 8-65 months), the event-free survival (EFS) was not different between the treatments (median 21 months versus 22 months; P = .28). Time to progression (TTP) was significantly longer after myeloablative treatment (25 months versus 31 months; P = .04). The overall survival (OS) was not different (50 months versus 47 months; P = .41). Intensified chemotherapy followed by myeloablative therapy as first-line treatment for multiple myeloma resulted in a higher CR and a longer TTP when compared with intensified chemotherapy alone. However, it did not result in a better EFS and OS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2002-03-0889

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 163

Metadata

Authors
Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E. G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P. W., Fibbe, W. E., Wittebol, S., Schouten, H. C., Kooy, M. V. M., Biesma, D. H., Baars, J. W., Slater, R., Steijaert, M. M. C., Buijt, I., & Lokhorst, H. M.
Venue
Blood
Published
2003-03-15
Volume
101
Issue
6
Pages
2144-2151
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2155618453
Cited by
163
References
2
FWCI
10.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. https://app.cochat.ai/papers/10.1182/blood-2002-03-0889
The paper
Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E. G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P. W., Fibbe, W. E., Wittebol, S., Schouten, H. C., Kooy, M. V. M., Biesma, D. H., Baars, J. W., Slater, R., Steijaert, M. M. C., Buijt, I., & Lokhorst, H. M. (2003). Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. https://doi.org/10.1182/blood-2002-03-0889

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.